Literature DB >> 25659844

[Postherpetic neuralgia].

G Goßrau1.   

Abstract

Postherpetic neuralgia is considered to be a neuropathic pain syndrome. Typically, patients experience pain in the dermatomes of skin lesions persisting for more than 3 months after skin restitution. About 10% of patients with herpes zoster develop postherpetic neuralgia. Its prevalence increases with age. Common clinical symptoms include continuous burning pain, sharp pain attacks, and allodynia. Additionally, sensory hyperactivation or loss in the affected skin area is present. Pathophysiology includes mechanisms of peripheral and central sensitization, based on damaged nerve fibers as the main mechanisms for pain generation and its maintenance. Clinical studies did show pain relief in postherpetic neuralgia after administration of antidepressants, antiepileptic drugs, opioids, and topical capsaicin and lidocaine. Nevertheless, about one third of patients do not respond to conventional treatment. Given the fact that postherpetic neuralgia is considered to be a chronic pain disease, a multidisciplinary treatment approach is necessary.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25659844     DOI: 10.1007/s00115-014-4233-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  23 in total

1.  The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles.

Authors:  A L Oaklander
Journal:  Pain       Date:  2001-05       Impact factor: 6.961

Review 2.  Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  Richard M Dubinsky; Janis Miyasaki
Journal:  Neurology       Date:  2009-12-30       Impact factor: 9.910

3.  Triggering of delayed-onset postherpetic neuralgia.

Authors:  G D Schott
Journal:  Lancet       Date:  1998-02-07       Impact factor: 79.321

Review 4.  Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus.

Authors:  T H Weller
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

Review 5.  Interventional management of neuropathic pain: NeuPSIG recommendations.

Authors:  Robert H Dworkin; Alec B O'Connor; Joel Kent; Sean C Mackey; Srinivasa N Raja; Brett R Stacey; Robert M Levy; Miroslav Backonja; Ralf Baron; Henning Harke; John D Loeser; Rolf-Detlef Treede; Dennis C Turk; Christopher D Wells
Journal:  Pain       Date:  2013-06-06       Impact factor: 6.961

6.  Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers.

Authors:  Elena K Krumova; Martina Zeller; Andrea Westermann; Christoph Maier
Journal:  Pain       Date:  2011-10-11       Impact factor: 6.961

7.  Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study.

Authors:  D K Kochar; P Garg; R A Bumb; S K Kochar; R D Mehta; R Beniwal; N Rawat
Journal:  QJM       Date:  2005-01

8.  A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia.

Authors:  C P Watson; K L Tyler; D R Bickers; L E Millikan; S Smith; E Coleman
Journal:  Clin Ther       Date:  1993 May-Jun       Impact factor: 3.393

9.  NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.

Authors:  Miroslav Backonja; Mark S Wallace; E Richard Blonsky; Barry J Cutler; Philip Malan; Richard Rauck; Jeffrey Tobias
Journal:  Lancet Neurol       Date:  2008-10-30       Impact factor: 44.182

10.  Herpes zoster in Germany: quantifying the burden of disease.

Authors:  Bernhard Ultsch; Anette Siedler; Thorsten Rieck; Thomas Reinhold; Gérard Krause; Ole Wichmann
Journal:  BMC Infect Dis       Date:  2011-06-16       Impact factor: 3.090

View more
  1 in total

Review 1.  [Use of intracutaneous or subcutaneous botulinum toxin for postherpetic neuralgia].

Authors:  L Halb; B J Amann; H Bornemann-Cimenti
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.